Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brepocitinib in active non-infectious uveitis
NCT06431373Phase 3Active, not recruiting
- Sponsor
- Priovant Therapeutics
- Start
- Sep 2024
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of brepocitinib in uveitis, sponsored by Priovant Therapeutics. Started Sep 2024; status: active, not recruiting.
02
Drugs
brepocitinib
03
Conditions
uveitis
Beyond the preview
Go deeper on NCT06431373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06431373.